12-Oct-2021 | Market Research Store
A group of scientists at the National University of Singapore(NUS) has recently developed a surveillance booster for the design of drug abuse. This research was led by Eric Chan from the NUS Department of Pharmacy. The team has accomplished success in developing three new urinary biomarkers that would help detect consumption of ADB-BUTINACA, a synthetically developed cannabinoidprescribed during emergencies. These new biomarkers have been developed in order todetermine the intakeof illicitdrugs such as cocaine, heroin, and LSD. This effort was made by the university to circumvent to precisely identify the culprits.
In an analysis conducted for almost two years, it was observed that new psychoactive substances fall under the third-largest category of drug abuse. Chan, the research head, while explaining the importance of the research said that metabolism and biomarkers were unable to detectADB-BUTINACA. He also mentioned that through the innovative research of detecting specific biomarkers,the team haschallenged the accurate detection ofsynthetic cannabinoids and is hoping to develop a drug-free world.
While talking about the researchcarried out in collaboration with the Analytical Toxicology Laboratory of Singapore Health Science Authority, Prof.Chan said that the team has started developing essential metabolites of ADB-BUTINACA by using a human liver enzyme. Later, its presence would be determined by detecting newly identified biomarkers released in urine. During the study, a total of fifteen metabolites and their pathways were identified. Out of which four were mentioned as urinary metabolites by the team.To detect the presence of synthetic cannabinoids, a panel of biomarkers was used. This panel comprises either one or a combination of three to four biomarkers. The team also discussed its future research plansfor properunderstanding of the deposition of synthetic cannabinoids in kidneys and their presence in the urine.
Read More:
https://www.marketresearchstore.com/market-insights/biosynthesis-of-cannabinoids-market-809653